Lilly eyes Merck and Sanofi's animal-health assets; Two Bristol SVPs to depart next month;

@FiercePharma:  Top Wyeth, Schering lawyers leave pharma. Report | Follow @FiercePharma 

> Eli Lilly is interested in animal-health assets that may be offered for sale as a result of Sanofi-Aventis and Merck's plan to combine their veterinary units. Report

> Two senior vice presidents at Bristol-Myers Squibb are leaving the company after COO Lamberto Andreotti was named to succeed James Cornelius as CEO. Report

> British drug delivery specialist SkyePharma says it is in the process of filing its Flutiform asthma drug for European approval, following recent setbacks in the United States. Story

> Genentech and Biogen Idec sued Genmab and partner GlaxoSmithKline (GSK) for patent infringement  based on GSK's manufacture, marketing and sale of Arzerra in the U.S. Release

> Baxter International has addressed problems the FDA found at a company plant in Belgium, resolving a warning letter the agency issued in January. Report

> Teva Pharmaceutical Industries got tentative FDA approval for its generic version of the anticoagulant, Argatroban injection, 100mg/mL. Release

> AspenBio strengthens leadership by adding Steve Lundy as CEO. Release 

> The United Arab Emirate's Health Ministry has put a temporary ban for GlaxoSmithKline's Rotarix vaccine. This is an oral vaccine given to infants less than 12 months of age to prevent rotavirus, that can cause vomiting, diarrhea and fever. Story

> The Generic Pharmaceutical Association, which represents companies that make low-cost generic drugs, spent $564,518 in the fourth quarter as it lobbied the White House, Congress and other federal agencies. Report

> Access Pharmaceuticals won approval from the Korean Food and Drug Administration for MuGard, an oncology supportive-care treatment for the management of oral mucositis. Release

> The board of directors of AstraZeneca Pharma approved a proposal to augment the company's tablet manufacturing plant and facility involving an estimated aggregate outlay of Rs 700 million. Report

> Kamada, which develops drugs on the basis of human plasma, mainly for respiratory conditions, received encouraging news from the FDA. The agency has informed Kamada by letter that it that it will receive a final response on approval of its ATT product, in the version administered intravenously, by July 1. Report

Biotech News

  @FierceBiotech: Small biotech offers its investors an easy way out. Article | Follow @FierceBiotech

  @JohnCFierce: HIV vax investigators are using social media to recruit for clinical trials. This is a hot trend in trial recruitment. | Follow @JohnCFierce

> Genentech is hiring. In an interview with BioSpace, Genentech's associate director of talent acquisition, Amanda Valentino, outlined plans to recruit more than 500 people this year. Item

> Researchers urged to resist early declaration of trial success. Article

> Salix shares surge on Xifaxan approval. Report

> The FDA's chief scientist, Jesse Goodman, has been doing some hard thinking about the FDA. And he's reached the conclusion that the agency is in dire need of rebuilding itself from the ground up--a task he says could take a decade. Story

Manufacturing News

> Process complexity could be barrier to biosimilars. Story

> DHL, American Airlines train drugmakers on cargo regulations. Report

> U.K. groups take on anti-counterfeiting projects. Article

> FDA relying on listings to find marketing abuses. Item

Vaccines News

> Pfizer, GSK vaccines could save nearly 1 million lives by 2015. News

> Pitt team tests promising vax for IBD, colon cancer. Item

> Vaccine makers settle France's H1N1 bill. Story

> Novavax shares surge on promising H1N1 trial data. Article

And Finally... China has overtaken India as the global epicenter of the diabetes epidemic. Report